Carol Ward

TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.

TL;DR: The surrogacy model supports use of PB-MRD as a primary end point in randomized clinical trials of chemoimmunotherapy in CLL and general applicability of MRD surrogacy for PFS across diverse patient characteristics, treatment regimens, and different treatment mechanisms of action is supported.

TL;DR: In this article, a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a protein in the biological sample was proposed.

TL;DR: In this paper, the authors discuss possible uses of MRD in the modern era of CLL, including its definition, measurement, and value as a surrogate endpoint in clinical trials, and its potential roles in clinical practice.

TL;DR: The evaluation of MRD response at the end of treatment as a surrogate endpoint for PFS in CLL is supported, based on a retrospective analysis of 3 multicenter, randomized, Phase 3 clinical trials, and a meta-regression model was developed to predict treatment effect on PFS using treatmentEffect on MRD.